Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on Apellis Pharmaceuticals (APLS – Research Report). The ...

APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Citi analyst Yigal Nochomovitz has reiterated their bullish stance on APLS stock, giving a Buy rating on September 20. Yigal ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following ...

Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $36.73 which represents a slight increase of $1.10 or 3.09% from the prior close of $35.63. The stock opened at $36.24 ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.